Health Canada Greenlights Sun Pharma’s Winlevi for Acne

Winlevi (clascoterone cream 1%) will be available in Canada this Fall.  Winlevi (clascoterone cream 1%) will be available in Canada this Fall. 

Health Canada has given its nod to Sun Pharma’s Winlevi (clascoterone cream 1%). 

Winlevi an androgen receptor inhibitor indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. It will be available in Canada this Fall. 

"Acne is a common condition due to hormonal triggers. However, there has been a gap in topical acne treatments which impact the hormonal cascade of acne for Canadians," says Dr. Jerry K.L. Tan, dermatology specialist and founder of The Healthy Image Center in Windsor, Ontario, in a news release. "I am thrilled that acne patients will soon have a new treatment option."

"Sun Pharma is committed to providing innovative dermatology medicines for Canadians, which fill the gap for necessary treatment options," adds Abhay Gandhi, North America CEO of Sun Pharma. "We are thrilled to provide a new topical treatment option for the millions of Canadians affected by acne."

"Our recent report, Breaking Out: a report on the acne patient experience in Canada, uncovers substantial treatment gaps for individuals with acne," says Sue Sherlock, executive director of the Acne and Rosacea Society of Canada. "One of our top recommendations for the industry has been to increase access to more treatments. We are pleased to see a new product available for Canadian patients."